PCSK9 Specific Neutra™ Antibody Products
Product listProprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a 72 kDa serine protease that is primarily expressed in the liver. Upon synthesis, PCSK9 undergoes self-catalyzed cleavage of its pro-domain.
Under physiological conditions, PCSK9 is involved in the equilibrium and homeostatic regulation of lipids, and the PCSK9 emanating from plasma and vascular cells can promote platelet activation and the recruitment of leukocytes.
Its Gene ID: 255738, UniProtKB ID: Q8NBP7, and OMIM ID: 607786.
Fig.1 PCSK9 self-catalyze.1
PCSK9 Biology
The primary biological function of PCSK9 is the regulation of cholesterol homeostasis, it binds to low-density lipoprotein receptor (LDL-R), promoting its endocytosis, lysosomal targeting of the receptor for degradation, and hence reduction of the clearance rate of LDL-C.
Conversely, LDL-R can mediate the clearance of PCSK9 from plasma regardless of its source. Studies have demonstrated that PCSK9 can promote hepatic lipogenesis via the mediation of LDL-R and apoE, thus regulating plasma lipid and lipoprotein levels.
Fig.2 PCSK9 and LDL-R.2
PCSK9 Pathology
As a key regulator of plasma cholesterol metabolism, PCSK9 has long been a hot target for hypercholesterolemia. Enhanced PCSK9 function reduces LDL-R levels in the liver leading to accumulation of LDL cholesterol in the plasma, making the host prone to dyslipidemia and cardiovascular diseases, while effective PCSK9 inhibition could prevent ischemic heart disease.
PCSK9 Inhibition
PCSK9 plays a role in the pathology of cardiovascular diseases through various mechanisms, making its targeted inhibition a feasible and potent strategy to intervene in the onset and progression of these diseases.
Monoclonal anti-PCSK9 antibodies or other inhibitors can promote cell membrane LDL-R recycling, and induce LDL-C uptake, thereby reducing cholesterol levels in plasma. A few PCSK9 inhibitors have entered the clinical or post-clinical stage, serving as effective alternatives to traditional drugs in the intervention of hyperlipidemia, atherosclerosis, and other cardiovascular diseases.
Fig.3 Mechanisms of PCSK9.3
Creative Biolabs professionally provides one-stop PCSK9-related services and dozens of products for clients all over the world. Supported by our superior neutralizing antibody and recombinant antibody services, we are confident in enhancing your exploration of the limitless potential of PCSK9.
REFERENCES
- Barale, Melchionda, et al. "PCSK9 Biology and Its Role in Atherothrombosis." International Journal of Molecular Sciences 22 (2021): 5880.
- Peterson, Editor, et al. "PCSK9 function and physiology." Journal of Lipid Research 49 (2008): 1303-1311.
- Liu, Chen, et al. "PCSK9 Inhibition: From Current Advances to Evolving Future." Cells 11 (2022): 2972.
